Sorin Group Italia S.R.L. appears in FDA premarket notification records as the applicant for cannula devices classified under 21 CFR 870.4210, the regulation for cardiopulmonary bypass vascular catheters, cannulae and tubing. The supplied filings identify the company at Via Statale 12 Nord, 86, Mirandola, Italy, with Luigi Vecchi listed as contact and, in one clearance letter, as Director RA. That address is a filing address, not a verified headquarters. The records describe single-use cannulae intended for a fluid path, with the Dual Stage and Tri Stage devices sharing the same product code and cardiovascular advisory committee. [1][2][4]

Documented cannula products

The two products named in the linked FDA records are Dual Stage Venous Cannulae and Tri Stage Venous Cannulae. Both carry product code DWF, device class 2, regulation number 870.4210, and the openFDA device name Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass. The cardiovascular advisory committee appears on both records, and each filing states that a summary is available. The Innolitics record for the Dual Stage device describes the devices as single-use and intended for a fluid path. [1][2][7]

A January 30, 2026 FDA letter to the company covers Dual Stage Venous Cannulae under the same regulation and product code, with a submission dated October 19, 2025 and received November 21, 2025. That letter states the agency determined the device substantially equivalent and describes non-clinical testing summarized in the submission as supporting equivalence to predicate devices, including unmodified venous cannulae cleared under K943934. [4]

Clearance dates and review types

The supplied portfolio snapshot, retrieved November 20, 2026, links two 510(k) records, both with decision code SESE, meaning substantially equivalent. The smaller record sample contains the same two entries: K263092 for Dual Stage Venous Cannulae, decided October 1, 2026, and K262052 for Tri Stage Venous Cannulae, decided September 28, 2026. These counts describe the supplied filings only, not total company sales, total portfolio or safety performance. [1][2]

The two records differ in review pathway. K263092 lists a Special clearance type, with the submission received September 3, 2026. K262052 lists a Traditional clearance type, received June 18, 2026. Neither record carries a third-party review flag, and both list the cardiovascular advisory committee for review. [1][2]

The FDA total product life cycle listing for this manufacturer includes links to K250610, K253671, K262052, K263092, K943934, K972503 and K981601 among the referenced premarket notifications. Only K262052 and K263092 appear in the supplied portfolio sample, so the other linked numbers are not described here beyond their presence in that listing. [6]

Applicant identity and limits of the record

The applicant name on the FDA records is Sorin Group Italia S.R.L., and the clearance letter is addressed to that legal entity. The public documents do not verify a parent company, brand family, website, customer base or commercial availability, and none should be inferred from the applicant name. The Mirandola address appears in filing data and correspondence rather than in a corporate registry document. [1][2][4]

The supplied portfolio snapshot contains no recall entries for this company. That absence reflects the retrieved sample only and is not evidence of postmarket safety performance. Clinical outcomes, patient-selection criteria and treatment guidance fall outside the scope of these premarket filing records. [1][2]